证券日报网讯1月27日，盈康生命（300143）在互动平台回答投资者提问时表示，公司始终对前沿技术 发展和公共卫生需求保持密切关注，任何新场景的拓展均会从社会价值、技术可行性及业务协同性等多 个维度进行审慎研究论证。后续如在该领域有达到信息披露标准的实质性进展，公司将严格按照规定履 行披露义务。 ...

Core Viewpoint - The company emphasizes the importance of accounts receivable management and has established strict internal measures to ensure effective collection and credit risk control [1] Group 1: Accounts Receivable Management - The company prioritizes customer repayment ability during the product sales process [1] - An internal policy for accounts receivable management has been implemented to enhance collection efforts and manage credit risk dynamically [1] Group 2: Research and Development - The company focuses on technological innovation as a core driver for development, continuously iterating on its operating systems, cloud computing, and information security product lines [1] - In the first half of 2025, the company's R&D investment reached 44.293 million, representing a year-on-year increase of 12.81% due to increased employee compensation and stock incentive plans [1]